drugset / Trial / NCT00801684
ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD
RandomizedCrossoverQuadruple-blindTreatment
Summary
The purpose of this study was to evaluate the efficacy, safety, and tolerability of single doses of trospium inhalation powder (TrIP) administered to subjects with chronic obstructive pulmonary disease (COPD).
Timeline
- Start
- 2009-02
- Primary completion
- 2009-04
- Completion
- 2009-07
Outcome
Met primary endpoint
registry analysis (superiority or other test); TrIP-2SS (100mcg) vs TrIP-2SS (100mcg) + Foradil (12mcg) vs TrIP-2D (100mcg) vs TrIP-2D (400mcg) vs Placebo; p <0.0001; ANCOVA NCT00801684 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Formoterol | Other / unclassified | 12 ug | Inhaled |
| Subject | Trospium | Small molecule | 100 ug | Inhaled |
| Subject | Trospium | Small molecule | 400 ug | Inhaled |